Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

APC 8015

Known as: APC-8015, APC8015, APC8015 Vaccine 
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… Expand
National Institutes of Health

Related topics

Related topics

3 relations
Dendritic CellsProvenge

Broader (1)

sipuleucel-T

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions
The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a… Expand
Review
2011
Review
2011
Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
As the most common malignancy among North American males, prostate cancer causes more than 30,000 deaths each year. After local… Expand
Review
2007
Review
2007
Advances in Prostate Cancer Immunotherapies
Prostate cancer is a major cause of mortality in men in the Western world. Although treatment of early stage prostate cancer with… Expand
Highly Cited
2006
Highly Cited
2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Highly Cited
2006
Highly Cited
2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local…
APC8015 (sipuleucel‐T) is a cellular prostate cancer vaccine containing autologous antigen‐presenting cells (APC) loaded with… Expand
Review
2006
Review
2006
Sipuleucel-T (APC8015) for prostate cancer
Sipuleucel-T (Provenge®; APC8015; Dendreon Corp, WA, USA) is a novel immunotherapeutic cellular product, which includes… Expand
Highly Cited
2005
Highly Cited
2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell… Expand
Highly Cited
2004
Highly Cited
2004
Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial
Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen‐independent… Expand
Review
2002
Review
2002
Technology evaluation: APC-8015, Dendreon.
  • B. Rini
  • Current opinion in molecular therapeutics
  • 2002
    • Corpus ID: 43594022
Dendreon (formerly Activated Cell Therapy), in association with the Mayo Clinic, is developing the dendritic cell therapy APC… Expand
Highly Cited
2000
Highly Cited
2000
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE